A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab in Patients With Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed by An Optional Open-Label Treatment Period

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety and Tolerability of Ponsegromab in Patients With Cancer, Cachexia, and Elevated Concentrations of GDF-15, Followed by An Optional Open-Label Treatment Period chavak11 Wed, 04/22/2026 - 08:00 Ponsegromab (PF-06946860) Ponsegromab (PF-06946860) PHASE II Mon, 11/21/2022 - 12:00 Wed, 04/23/2025 - 12:00 NCT05546476 C3651003 Public Disclosure Synopsis.pdf (111.55 KB) N https://clinicaltrials.gov/study/NCT05546476?term=C3651003&viewType=Card&rank=1 C3651003